Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 72
- Registration Number
- NCT00523328
- Locations
- 🇬🇧
Coordinating Research Site, Newcastle, United Kingdom
Natalizumab High Titer Immunogenicity and Safety
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: BG00002-E (natalizumab high titer)
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 113
- Registration Number
- NCT00516893
- Locations
- 🇺🇸
Research site, Round Rock, Texas, United States
🇺🇸Research Site, Milwaukee, Wisconsin, United States
Tysabri Observational Program
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 6620
- Registration Number
- NCT00493298
- Locations
- 🇬🇧
Research site, Stoke on Trent, United Kingdom
🇸🇰Research Site, Bratislava, Slovakia
🇫🇷Research site ,1 Allée du Château- Dr Wagner, Ars-Laquenexy, France
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00493116
- Locations
- 🇳🇿
Research Site, Hamilton, New Zealand
🇦🇺Coordinating Research Site, NSW, Australia
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 14
- Registration Number
- NCT00492466
- Locations
- 🇫🇮
Coordinating Research Site, Turku, Finland
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: low immunogenic interferon-beta-1a
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 3
- Registration Number
- NCT00493077
- Locations
- 🇸🇪
Coordinating Research Site, Huddinge, Sweden
🇸🇪Research Site, Stockholm, Sweden
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 380
- Registration Number
- NCT00492765
- Locations
- 🇩🇰
Coordinating Research Site, Copenhagen, Denmark
GER-009-06-AVX Early Therapy in Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 230
- Registration Number
- NCT00492570
GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers
- Conditions
- Bipolar Disorder
- Interventions
- Drug: GSK drugOther: PlaceboOther: Lamictal
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 50
- Registration Number
- NCT00488566
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 4296
- Registration Number
- NCT00483847
- Locations
- 🇩🇪
There are multiple sites throughout Europe in this clinical trial. Contact Advanced Medical Services (AMS)., Mannheim, Germany